Greg Walden actually said...
Extending immunosuppressive drug coverage for the lifetime of kidney patients is a cost-effective way for the Federal Government to improve clinical outcomes for those with end-stage renal disease.
Context
Walden advocates for lifetime coverage of immunosuppressive drugs for kidney patients to improve outcomes.
01/07/2020